Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
Wednesday, November 20, 2024Boehringer Ingelheim a leading researchdriven biopharmaceutical company has been lifted to th place in the Access to Medicine Index ATMI up from th in This improvement reflects the companys strategic shift of prioritizing Health Equity as its prima...
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
Wednesday, November 20, 2024Pfizer Inc announced today that the European Commission EC has granted marketing authorization for HYMPAVZI marstacimab for the routine prophylaxis of bleeding episodes in patients years of age and older weighing at least kg with severe hemophilia...
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
Tuesday, November 19, 2024Samsung Bioepis Co Ltd and Biogen Inc announced that the European Commission EC has approved OPUVIZ mgmL solution for injection in a vial a biosimilar referencing Eylea aflibercept developed and registered by Samsung Bioepis
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Tuesday, November 19, 2024UCB and Biogen Inc today presented detailed results from the Phase PHOENYCS GO study evaluating dapirolizumab pegol DZP a novel Fcfree antiCDL drug candidate demonstrating significant clinical improvement in disease activity in people living with mo...
BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius
Tuesday, November 19, 2024BioPharmaSpec the leading global Contract Research Organization CRO for Discovery and Preclinical Characterization of Biopharmaceuticals has officially announced three new European facilities The new facilities will focus on discovery and RD services
Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer
Monday, November 18, 2024AstraZenecas Tagrisso osimertinib has been recommended for approval in the European Union EU for the treatment of adult patients with locally advanced unresectable nonsmall cell lung cancer NSCLC whose tumours have epidermal growth factor receptor EG...
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
Monday, November 18, 2024BioCryst Pharmaceuticals Inctoday announced that the Health Services Executive HSE in Ireland has recommended ORLADEYO berotralstat for the routine prevention of recurrent attacks of hereditary angioedema HAE in eligible patients years and older
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Saturday, November 16, 2024Numab Therapeutics AG a clinical stage biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology and Kaken Pharmaceutical Co Ltd Kaken an RD driven pharmaceutical company in Japan announced today a...
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Friday, November 15, 2024Cellectar Biosciences Inc a latestage clinical biopharmaceutical company focused on the discovery development and commercialization of drugs for the treatment of cancer today announced the signing of a strategic supply agreement with NorthStar Medica...
New BIMZELX® (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis
Friday, November 15, 2024UCB a global biopharmaceutical company today announced the presentation of new twoyear data confirming a sustained clinical response for the ILA and ILF inhibitor bimekizumabbkzx in adults with active psoriatic arthritis PsA and those with active non...
